Business Description
Zura Bio Ltd
NAICS : 541714
SIC : 2834
ISIN : KYG9TY5A1016
Share Class Description:
ZURA: Ordinary Shares - Class ACompare
Compare
Traded in other countries / regions
ZURA.USA94E.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2023-03-21Description
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.8 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Future 3-5Y EPS without NRI Growth Rate Estimate | -21.16 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 28.04 | |||||
| 9-Day RSI | 35.84 | |||||
| 14-Day RSI | 40.17 | |||||
| 3-1 Month Momentum % | -14.77 | |||||
| 6-1 Month Momentum % | -59.6 | |||||
| 12-1 Month Momentum % | -72.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.14 | |||||
| Quick Ratio | 8.14 | |||||
| Cash Ratio | 8.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -95.45 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -47.36 | |||||
| ROA % | -37.81 | |||||
| ROIC % | -4441.58 | |||||
| ROC (Joel Greenblatt) % | -120116.36 | |||||
| ROCE % | -45.1 | |||||
| Moat score | 3 | |||||
| Tariff score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.55 | |||||
| Price-to-Tangible-Book | 0.55 | |||||
| EV-to-EBIT | 1.4 | |||||
| EV-to-Forward-EBIT | -2.41 | |||||
| EV-to-EBITDA | 1.4 | |||||
| EV-to-FCF | 2.7 | |||||
| Price-to-Net-Current-Asset-Value | 0.56 | |||||
| Price-to-Net-Cash | 0.56 | |||||
| Earnings Yield (Greenblatt) % | 71.43 | |||||
| FCF Yield % | -49.46 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers